These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3800686)

  • 21. Plasma exchange and immunosuppressive drug treatment in myasthenia gravis: no evidence for synergy.
    Hawkey CJ; Newsom-Davis J; Vincent A
    J Neurol Neurosurg Psychiatry; 1981 Jun; 44(6):469-75. PubMed ID: 7276959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.
    J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1157-63. PubMed ID: 8229026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.
    Fattorossi A; Battaglia A; Buzzonetti A; Ciaraffa F; Scambia G; Evoli A
    Immunology; 2005 Sep; 116(1):134-41. PubMed ID: 16108825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Symposium on therapeutic controversies. Myasthenia gravis. Steroids and immunosuppressive drugs.
    Johns TR; Howard FM
    Trans Am Neurol Assoc; 1978; 103():278-81. PubMed ID: 229611
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis.
    Matell G
    Ann N Y Acad Sci; 1987; 505():589-94. PubMed ID: 3479940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.
    Heckmann JM; Rawoot A; Bateman K; Renison R; Badri M
    BMC Neurol; 2011 Aug; 11():97. PubMed ID: 21819556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myasthenia gravis: how to treat?
    Tireli H; Karlikaya G; Tutkavul K; Akpinar A; Okay T
    Acta Myol; 2004 Dec; 23(3):140-5. PubMed ID: 15938570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fluocortolon, azathioprine and cyclophosphamide in the therapy of myasthenia gravis].
    Jusić A; Zagar M
    Neurologija; 1979; 27(1-4):167-79. PubMed ID: 400406
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term prednisone followed by thymectomy in myasthenia gravis.
    Mann JD; Johns TR; Campa JF; Muller WH
    Ann N Y Acad Sci; 1976; 274():608-22. PubMed ID: 1066998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remission of myasthenia gravis following plasma-exchange.
    Pinching AJ; Peters DK
    Lancet; 1976 Dec; 2(8000):1373-6. PubMed ID: 63848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of immunosuppressive drugs (azathioprine).
    Mertens HG; Hertel G; Reuther P; Ricker K
    Ann N Y Acad Sci; 1981; 377():691-9. PubMed ID: 6951493
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressive drugs in treatment of myasthenia gravis.
    Rowland LP
    Ann N Y Acad Sci; 1971 Sep; 183():351-7. PubMed ID: 5287832
    [No Abstract]   [Full Text] [Related]  

  • 35. Randomized Trial of Thymectomy in Myasthenia Gravis.
    Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BR; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Garcia Ramos GS; Verschuuren JJ; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Odenkirchen J; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
    N Engl J Med; 2016 Aug; 375(6):511-22. PubMed ID: 27509100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The course of myasthenia gravis in patients treated with corticosteroids, azathioprine, and plasmapheresis.
    Cornelio F; Peluchetti D; Mantegazza R; Sghirlanzoni A; Collarile C
    Ann N Y Acad Sci; 1987; 505():517-25. PubMed ID: 3479934
    [No Abstract]   [Full Text] [Related]  

  • 37. [Amount of circulating acetylcholine receptor antibodies in the course of myasthenia, following thymectomy and in immunosuppressive therapy].
    Patzold U; Kalies I; Haas J; Ginda EM
    Nervenarzt; 1984 Aug; 55(8):426-31. PubMed ID: 6483064
    [No Abstract]   [Full Text] [Related]  

  • 38. Plasmapheresis therapy in myasthenia gravis.
    Dau PC
    Muscle Nerve; 1980; 3(6):468-82. PubMed ID: 7453714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapy of myasthenia gravis].
    Jerusalem F
    Dtsch Med Wochenschr; 1977 Aug; 102(32):1160-3. PubMed ID: 196820
    [No Abstract]   [Full Text] [Related]  

  • 40. [Side-effects of azathioprine and cyclophosphamide therapy].
    Grgić Z
    Neurologija; 1979; 27(1-4):201-4. PubMed ID: 262009
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.